Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Malignant pleural mesothelioma (MPM) often overexpresses the epidermal growth factor receptor (EGFR, ErbB1).
• Targeting EGFR is a potential therapeutic strategy for MPM.

Purpose of the Study:

• To evaluate the efficacy of lapatinib, a dual EGFR/HER2 inhibitor, against a panel of MPM cell lines.
• To investigate the molecular mechanisms underlying lapatinib sensitivity and resistance in MPM.
• To explore combination therapies involving lapatinib and signal transduction inhibitors.

Main Methods:

• Treatment of 10 MPM cell lines with lapatinib.
• Analysis of EGFR pathway components (ErbB1-4, phospho-Akt, Akt, phospho-ERK1/2, p27) via Western blotting.
• Assessment of cell cycle arrest and growth inhibition (IC50 determination).
• Combination studies with lapatinib and signal transduction inhibitors (U0126, LY294002, rapamycin).

Main Results:

• Two of ten MPM cell lines (H2373, H2452) exhibited sensitivity to lapatinib, with G1/S cell cycle arrest and growth inhibition.
• No correlation was found between baseline EGFR pathway component levels and lapatinib response.
• Sensitive cell lines showed decreased phospho-Akt/ERK1/2 and increased p27 upon lapatinib treatment.
• Combinations of lapatinib with U0126, LY294002, or rapamycin enhanced growth inhibition in sensitive lines but not resistant ones.

Conclusions:

• EGFR (ErbB1) inhibition alone is effective only for a subset of mesotheliomas.
• Combination therapy with EGFR inhibitors and signal transduction inhibitors may improve efficacy in MPM.
• Targeting multiple signaling pathways simultaneously could be crucial for inhibiting the majority of MPM cell growth.